JP2010536854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536854A5 JP2010536854A5 JP2010521876A JP2010521876A JP2010536854A5 JP 2010536854 A5 JP2010536854 A5 JP 2010536854A5 JP 2010521876 A JP2010521876 A JP 2010521876A JP 2010521876 A JP2010521876 A JP 2010521876A JP 2010536854 A5 JP2010536854 A5 JP 2010536854A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- administered
- dosage
- range
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- CATMPQFFVNKDEY-YPMHNXCESA-N Golotimod Chemical compound C1=CC=C2C(C[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(O)=O)=CNC2=C1 CATMPQFFVNKDEY-YPMHNXCESA-N 0.000 claims description 16
- 108010049353 golotimod Proteins 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 9
- 230000005855 radiation Effects 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 230000037396 body weight Effects 0.000 claims 7
- 206010027476 Metastases Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- 229930182827 D-tryptophan Chemical group 0.000 claims 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical group C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-Tryptophan Natural products C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims 1
- 108010033276 Peptide Fragments Chemical group 0.000 claims 1
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- -1 heterocyclic amino acid Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000032646 lung growth Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 0 *NC(**=O)C(O)=O Chemical compound *NC(**=O)C(O)=O 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95753007P | 2007-08-23 | 2007-08-23 | |
| PCT/US2008/009932 WO2009025830A1 (en) | 2007-08-23 | 2008-08-21 | Treatment of lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010536854A JP2010536854A (ja) | 2010-12-02 |
| JP2010536854A5 true JP2010536854A5 (enExample) | 2011-09-29 |
Family
ID=40378469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521876A Pending JP2010536854A (ja) | 2007-08-23 | 2008-08-21 | 肺ガンの治療 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110189305A1 (enExample) |
| EP (1) | EP2192835A4 (enExample) |
| JP (1) | JP2010536854A (enExample) |
| KR (1) | KR20100063078A (enExample) |
| CN (1) | CN101842009A (enExample) |
| AU (1) | AU2008289522A1 (enExample) |
| BR (1) | BRPI0815772A2 (enExample) |
| CA (1) | CA2697261A1 (enExample) |
| EA (1) | EA201070295A1 (enExample) |
| MX (1) | MX2010002046A (enExample) |
| NZ (1) | NZ584065A (enExample) |
| UA (1) | UA98508C2 (enExample) |
| WO (1) | WO2009025830A1 (enExample) |
| ZA (1) | ZA201001876B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA96980C2 (ru) | 2007-02-13 | 2011-12-26 | Сайклон Фармасютикалс, Инк. | Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки |
| RU2519738C2 (ru) * | 2011-12-12 | 2014-06-20 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации | Способ лечения рака легкого |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5902790A (en) * | 1995-10-03 | 1999-05-11 | Cytran, Inc. | Pharmaceutical angiostatic dipeptide compositions and method of use thereof |
| US5744452A (en) * | 1995-11-28 | 1998-04-28 | Edward T. Wei | γ-L-glutamyl containing immunomodulator compounds and methods therewith |
| US5916878A (en) * | 1995-11-28 | 1999-06-29 | Edward T. Wei | γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith |
| RU2141483C1 (ru) * | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
| RU2229892C2 (ru) * | 2001-06-08 | 2004-06-10 | Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" | Способ лечения туберкулеза легких |
-
2008
- 2008-08-21 UA UAA201003197A patent/UA98508C2/ru unknown
- 2008-08-21 KR KR1020107006244A patent/KR20100063078A/ko not_active Withdrawn
- 2008-08-21 BR BRPI0815772-3A2A patent/BRPI0815772A2/pt not_active IP Right Cessation
- 2008-08-21 WO PCT/US2008/009932 patent/WO2009025830A1/en not_active Ceased
- 2008-08-21 CN CN200880112940A patent/CN101842009A/zh active Pending
- 2008-08-21 AU AU2008289522A patent/AU2008289522A1/en not_active Abandoned
- 2008-08-21 JP JP2010521876A patent/JP2010536854A/ja active Pending
- 2008-08-21 EP EP08795475A patent/EP2192835A4/en not_active Withdrawn
- 2008-08-21 EA EA201070295A patent/EA201070295A1/ru unknown
- 2008-08-21 US US12/674,646 patent/US20110189305A1/en not_active Abandoned
- 2008-08-21 CA CA2697261A patent/CA2697261A1/en not_active Abandoned
- 2008-08-21 MX MX2010002046A patent/MX2010002046A/es not_active Application Discontinuation
- 2008-08-21 NZ NZ584065A patent/NZ584065A/en not_active IP Right Cessation
-
2010
- 2010-03-16 ZA ZA2010/01876A patent/ZA201001876B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1303294A (zh) | 抗肿瘤剂 | |
| JP2019503365A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JPWO1999051246A1 (ja) | 抗腫瘍剤 | |
| US20130310414A1 (en) | Therapeutic or prophylactic agent for cachexia | |
| JP2018184465A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| AU2012257760A1 (en) | Method for treatment of advanced solid tumors | |
| WO2020081971A1 (en) | Combinations for immune-modulation in cancer treatment | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| JP2012504161A5 (enExample) | ||
| JP2010536854A5 (enExample) | ||
| CN1491126A (zh) | 癌症治疗方法 | |
| EP4230205A1 (en) | Antitumor pharmaceutical composition and application thereof | |
| Wang et al. | Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis | |
| CN110354261B (zh) | 喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途 | |
| US10668080B2 (en) | Phosphaplatin compounds as therapeutic agents for treatment of bone or blood cancers | |
| US7906486B2 (en) | Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa | |
| RU2007147594A (ru) | Комбинации производных индакатерола и других агентов для лечения заболеваний дыхательных путей | |
| US10702534B2 (en) | Compositions and methods relating to the radioprotective effects of apilimod | |
| CN1505511A (zh) | 吡啶并吲哚酮类衍生物用于制备药物的用途 | |
| CN106421796B (zh) | 索拉菲尼联合ccr4拮抗剂在抑制癌生长及转移中的应用 | |
| US20110189305A1 (en) | Treatment of lung cancer | |
| RU2228752C1 (ru) | Фармацевтическая композиция, содержащая ондансетрон и бензамид | |
| JPH0840903A (ja) | 抗癌剤により誘発される末梢神経障害を予防するための医薬組成物 |